1
|
Alfarano C, Foussal C, Lairez O, Calise D, Attané C, Anesia R, Daviaud D, Wanecq E, Parini A, Valet P, Kunduzova O. Transition from metabolic adaptation to maladaptation of the heart in obesity: role of apelin. Int J Obes (Lond) 2014; 39:312-20. [PMID: 25027224 PMCID: PMC4326962 DOI: 10.1038/ijo.2014.122] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Revised: 06/15/2014] [Accepted: 06/17/2014] [Indexed: 11/10/2022]
Abstract
Background/Objectives: Impaired energy metabolism is the defining characteristic of obesity-related heart failure. The adipocyte-derived peptide apelin has a role in the regulation of cardiovascular and metabolic homeostasis and may contribute to the link between obesity, energy metabolism and cardiac function. Here we investigate the role of apelin in the transition from metabolic adaptation to maladaptation of the heart in obese state. Methods: Adult male C57BL/6J, apelin knock-out (KO) or wild-type mice were fed a high-fat diet (HFD) for 18 weeks. To induce heart failure, mice were subjected to pressure overload after 18 weeks of HFD. Long-term effects of apelin on fatty acid (FA) oxidation, glucose metabolism, cardiac function and mitochondrial changes were evaluated in HFD-fed mice after 4 weeks of pressure overload. Cardiomyocytes from HFD-fed mice were isolated for analysis of metabolic responses. Results: In HFD-fed mice, pressure overload-induced transition from hypertrophy to heart failure is associated with reduced FA utilization (P<0.05), accelerated glucose oxidation (P<0.05) and mitochondrial damage. Treatment of HFD-fed mice with apelin for 4 weeks prevented pressure overload-induced decline in FA metabolism (P<0.05) and mitochondrial defects. Furthermore, apelin treatment lowered fasting plasma glucose (P<0.01), improved glucose tolerance (P<0.05) and preserved cardiac function (P<0.05) in HFD-fed mice subjected to pressure overload. In apelin KO HFD-fed mice, spontaneous cardiac dysfunction is associated with reduced FA oxidation (P<0.001) and increased glucose oxidation (P<0.05). In isolated cardiomyocytes, apelin stimulated FA oxidation in a dose-dependent manner and this effect was prevented by small interfering RNA sirtuin 3 knockdown. Conclusions: These data suggest that obesity-related decline in cardiac function is associated with defective myocardial energy metabolism and mitochondrial abnormalities. Furthermore, our work points for therapeutic potential of apelin to prevent myocardial metabolic abnormalities in heart failure paired with obesity.
Collapse
Affiliation(s)
- C Alfarano
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| | - C Foussal
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| | - O Lairez
- National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France
| | - D Calise
- 1] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France [2] US006, Microsurgery Services, Toulouse, France
| | - C Attané
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| | - R Anesia
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| | - D Daviaud
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| | - E Wanecq
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| | - A Parini
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| | - P Valet
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| | - O Kunduzova
- 1] National Institute of Health and Medical Research (INSERM) U1048, Toulouse, France [2] University of Toulouse, UPS, Institute of Metabolic and Cardiovascular Diseases, Toulouse, France
| |
Collapse
|
2
|
Kuma A, Yamada S, Miyamoto T, Serino R, Tamura M, Otsuji Y, Kohno K, Cho WY, Kim MG, Jo SK, Kim HK, Jado JC, Humanes B, Lopez-Parra V, Camano S, Lara JM, Cercenado E, Tejedor A, Lazaro A, Jansen M, Castellano G, Stasi A, Intini A, Gigante M, Di Palma AM, Divella C, Netti GS, Prattichizzo C, Pontrelli P, Crovace A, Staffieri F, Fiaccadori E, Brienza N, Grandaliano G, Pertosa GB, Gesualdo L, Xanthopoulou K, Tsouchnikas I, Ouzounidis G, Kokaraki G, Lagoudaki R, Simeonidou C, Karkavelas G, Spandou E, Tsakiris D, Xanthopoulou K, Tsouchnikas I, Ouzounidis G, Kokaraki G, Simeonidou C, Karkavelas G, Spandou E, Kallaras K, Tsakiris D, Schneider R, Meusel M, Betz BB, Held C, Moller-Ehrlich K, Buttner-Herold M, Wanner C, Michael G, Sauvant C, Hosszu A, Antal Z, Hodrea J, Koszegi S, Banki NF, Wagner L, Lenart L, Vannay A, Szabo AJ, Fekete A, Michael A, Faga T, Navarra M, Andreucci M, Lemoine S, Pillot B, Rabeyrin M, Varennes A, Ovize M, Juillard L, Gomes Santana L, Silva Almeida W, Schor N, Watanabe M, Fonseca CD, Pessoa EA, Mendonca MH, Fernandes SM, Borges FT, Vattimo MF, Ow CPC, Tassone F, Koeners MP, Malpas SC, Evans RG, Alfarano C, Guardia MA, Lluel P, Palea S, Young GH, Wu VC, Choi DE, Jeong JY, Chang YK, Chung S, Na KR, Kim SS, Lee KW, Choi DE, Jeong JY, Chung S, Chang YK, Na KR, Kim SS, Lee KW, Yang Y, Zhang L, Fu P, Zhao Y, Zhang X, Jadot I, Decleves AE, Colombaro V, Martin B, Voisin V, Habsch I, Deprez E, Nortier J, Caron N, Iwakura T, Fujikura T, Ohashi N, Yasuda H, Fujigaki Y, Vasco CF, Watanabe M, Fonseca CD, Vattimo MDFF, Draibe J, Y ld r m Y, Aba O, Y lmaz Z, Kadiroglu AK, Y lmaz ME, Gul M, Ketani A, Colpan L, Neiva LBDM, Borges FT, Fonseca CD, Watanabe M, Vattimo MDFF, Suller Garcia J, Oliveira ASD, Naves MA, Borges FT, Schor N, Van Swelm RPL, Wetzels JFM, Verweij VGM, Laarakkers CMM, Pertijs JCLM, Swinkels DW, Masereeuw R, Sereno J, Rodrigues-Santos P, Vala H, Rocha-Pereira P, Fernandes J, Santos-Silva A, Teixeira F, Reis F, Altuntas A, Yilmaz HR, Altuntas A, Uz E, Demir M, Gokcimen A, Bayram DS, Aksu O, Sezer MT, Yang KH, Jung YJ, Kim D, Lee AS, Lee S, Kang KP, Park SK, Kim W, Junglee NA, Searell CR, Jibani MM, Macdonald JH, Wu CC, Chen CC, Lu KC, Lin YF, Estrela GR, Wasinski F, Pereira R, Malheiros D, Camara NOS, Araujo RC, Ramos MF, Passos CDS, Razvickas CV, Borges F, Ormanji M, Schor N, Plotnikov E, Morosanova M, Pevzner I, Zorova L, Manskikh V, Skulachev M, Skulachev V, Zorov D, Pinto CF, Watanabe M, Fonseca CD, Vattimo M. EXPERIMENTAL ACUTE KIDNEY INJURY. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Alfarano C, Roubeix C, Chaaya R, Ceccaldi C, Calise D, Mias C, Cussac D, Bascands JL, Parini A. Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats. Cell Transplant 2012; 21:2009-19. [PMID: 22525800 DOI: 10.3727/096368912x640448] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Ischemia-reperfusion and immunosuppressive therapy are a major cause of progressive renal failure after kidney transplantation. Recent studies have shown that administration of bone marrow mesenchymal stem cells (MSCs) improves kidney functional recovery in the acute phase of post ischemia-reperfusion injury. In the present study, we used an original model of renal ischemia-reperfusion in immunosuppressed rats (NIRC) to investigate the effects of bone marrow MSCs on progression of chronic renal failure and the mechanisms potentially involved. Left renal ischemia-reperfusion (IR) was induced in unilateral nephrectomized Lewis rats. After IR, rats were treated daily with cyclosporine (10 mg/kg SC) for 28 days. MSCs were injected into the kidney at day 7 after IR. At day 28 after IR, kidneys were removed for histomorphological, biochemical, and gene expression analysis. The effect of conditioned media from MSCs on epithelial-mesenchymal transition was studied in vitro on HK2 cells. Our results show that, as compared to untreated NIRC rats, rats treated by intrarenal injection of MSCs 7 days after IR displayed improvement in renal function, reduction of interstitial fibrosis, and decrease in chronic tubule injury. These effects were associated with a decrease in interstitial α-SMA accumulation and MMP2 activity, markers of fibroblast/fibroblast-like cell activation, and renal remodeling, respectively. Finally, experiments in vitro showed that MSC-conditioned medium prevented epithelial-mesenchymal transition induced by TGF-β in HK2 cells. In conclusion, our results show that, in immunosuppressed animals, a single intrarenal administration of MSCs reduced renal fibrosis and promoted the recovery of renal function.
Collapse
Affiliation(s)
- C Alfarano
- Inserm, UMR 1048, Institute of Metabolic and Cardiovascular Diseases (I2MC), Toulouse, France
| | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Alfarano C, Sartiani L, Nediani C, Mannucci E, Mugelli A, Cerbai E, Raimondi L. Functional coupling of angiotensin II type 1 receptor with insulin resistance of energy substrate uptakes in immortalized cardiomyocytes (HL-1 cells). Br J Pharmacol 2007; 153:907-14. [PMID: 17982475 DOI: 10.1038/sj.bjp.0707563] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND AND PURPOSE Increased angiotensin II levels and insulin resistance coexist at the early stages of cardiomyopathies. To determine whether angiotensin II increases insulin resistance in cardiomyocytes, we studied the effect of angiotensin II on basal and insulin-stimulated transport rate of energy substrates in immortalized cardiomyocytes (HL-1 cells). EXPERIMENTAL APPROACH Glucose and palmitic acid uptakes were measured using [(3)H]2-deoxy-D-glucose and [(14)C]palmitic acid, respectively, in cells exposed or not exposed to angiotensin II (100 nM), angiotensin II plus irbesartan or PD123319, type 1 and 2 receptor antagonists, or PD98059, an inhibitor of ERK1/2 activation. Cell viability, DNA, protein synthesis and surface area were evaluated by the MTT test, [(3)H]thymydine, [(3)H]leucine and morphometric analysis, respectively. Type 1 receptor levels were measured by western blot analysis. KEY RESULTS Basal uptakes of glucose and palmitic acid by HL-1 cells (0.37+/-0.07 and 7.31+/-0.22 pmol per 10(4)cells per min, respectively) were both stimulated by 100 nM insulin (+91 and +64%, respectively). Cells exposed to angiotensin II remained viable and did not show signs of hypertrophy. In these conditions, the basal palmitic acid uptake of the cells increased (11.41+/-0.46 pmol per 10(4) cells per min) and insulin failed to stimulate the uptake of glucose and fatty acids. Changes in the rate of uptake of energy substrates were prevented or significantly reduced by irbesartan or PD98059. CONCLUSIONS AND IMPLICATIONS Angiotensin II is a candidate for increasing insulin resistance in cardiomyocytes. Our results suggest a further mechanism for the cardiovascular protection offered by the angiotensin II type 1 receptor blockers.
Collapse
Affiliation(s)
- C Alfarano
- Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy
| | | | | | | | | | | | | |
Collapse
|
6
|
Alfarano C, Andrade CE, Anthony K, Bahroos N, Bajec M, Bantoft K, Betel D, Bobechko B, Boutilier K, Burgess E, Buzadzija K, Cavero R, D'Abreo C, Donaldson I, Dorairajoo D, Dumontier MJ, Dumontier MR, Earles V, Farrall R, Feldman H, Garderman E, Gong Y, Gonzaga R, Grytsan V, Gryz E, Gu V, Haldorsen E, Halupa A, Haw R, Hrvojic A, Hurrell L, Isserlin R, Jack F, Juma F, Khan A, Kon T, Konopinsky S, Le V, Lee E, Ling S, Magidin M, Moniakis J, Montojo J, Moore S, Muskat B, Ng I, Paraiso JP, Parker B, Pintilie G, Pirone R, Salama JJ, Sgro S, Shan T, Shu Y, Siew J, Skinner D, Snyder K, Stasiuk R, Strumpf D, Tuekam B, Tao S, Wang Z, White M, Willis R, Wolting C, Wong S, Wrong A, Xin C, Yao R, Yates B, Zhang S, Zheng K, Pawson T, Ouellette BFF, Hogue CWV. The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res 2005; 33:D418-24. [PMID: 15608229 PMCID: PMC540005 DOI: 10.1093/nar/gki051] [Citation(s) in RCA: 447] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
The Biomolecular Interaction Network Database (BIND) (http://bind.ca) archives biomolecular interaction, reaction, complex and pathway information. Our aim is to curate the details about molecular interactions that arise from published experimental research and to provide this information, as well as tools to enable data analysis, freely to researchers worldwide. BIND data are curated into a comprehensive machine-readable archive of computable information and provides users with methods to discover interactions and molecular mechanisms. BIND has worked to develop new methods for visualization that amplify the underlying annotation of genes and proteins to facilitate the study of molecular interaction networks. BIND has maintained an open database policy since its inception in 1999. Data growth has proceeded at a tremendous rate, approaching over 100 000 records. New services provided include a new BIND Query and Submission interface, a Standard Object Access Protocol service and the Small Molecule Interaction Database (http://smid.blueprint.org) that allows users to determine probable small molecule binding sites of new sequences and examine conserved binding residues.
Collapse
Affiliation(s)
- C Alfarano
- The Blueprint Initiative of Mount Sinai Hospital, 600 University Avenue, Toronto, ON, Canada M5G 1X5
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|